Notch signaling pathway

Notch signaling pathway
Name	Notch signaling pathway
Caption	Simplified diagram of Notch receptor activation
Organism	Metazoa
Discovered	1917
Discoverer	Thomas Hunt Morgan

Notch signaling pathway

The Notch signaling pathway is a conserved cell–cell communication mechanism that governs cell fate decisions during embryogenesis and adult tissue homeostasis. It was first characterized through genetic studies in Drosophila melanogaster and later linked to developmental processes in Mus musculus, Danio rerio, and humans. Core discoveries tying Notch to disease have involved research institutions such as Johns Hopkins University, Cold Spring Harbor Laboratory, and Max Planck Society.

Overview

Notch signaling operates via direct interactions between membrane-bound ligands and receptors on neighboring cells as seen in studies from Caltech, Harvard University, and MIT. Early work by Thomas Hunt Morgan and subsequent genetic screens in Drosophila melanogaster revealed phenotypes that influenced research at laboratories including University of Cambridge and University of California, Berkeley. Evolutionary conservation across taxa such as Caenorhabditis elegans, Xenopus laevis, and humans highlights its role in processes studied at centers like European Molecular Biology Laboratory and Stanford University School of Medicine.

Components and Mechanism

The pathway centers on single-pass transmembrane receptors (Notch1–4 in humans) and canonical DSL-family ligands such as Delta-like 1, Delta-like 3, Delta-like 4, Jagged1, and Jagged2; these were characterized in molecular biology programs at institutions like Yale University and UCLA. Ligand–receptor engagement triggers sequential proteolytic cleavages by metalloproteases of the ADAM family and intramembrane cleavage by the gamma-secretase complex, components of which were elucidated in work involving Salk Institute and Mayo Clinic. Release of the Notch intracellular domain translocates to the nucleus to form transcriptional complexes with CSL-family DNA-binding proteins (also known as RBPJ) and coactivators such as Mastermind-like proteins, modulating target genes including members of the HES and HEY families, genes also studied at institutions like Karolinska Institutet and University of Chicago.

Roles in Development and Physiology

Notch signaling directs binary fate decisions during neurogenesis and lateral inhibition as first described in Drosophila melanogaster neuroblasts, with parallels in vertebrate neural development explored at Columbia University and University College London. It regulates somitogenesis and boundary formation during segmentation in models such as Danio rerio and Mus musculus, linking research from Max Planck Institute and National Institutes of Health (United States). Notch controls angiogenesis and vascular branching through DLL4–Notch1 interactions, findings relevant to translational work at Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. In hematopoiesis, Notch influences T-cell lineage commitment and stem cell maintenance, topics investigated at Fred Hutchinson Cancer Research Center and Weill Cornell Medicine.

Regulation and Crosstalk with Other Pathways

Notch activity is modulated by post-translational modifications including glycosylation by Fringe family enzymes first characterized in developmental genetics labs at University of Wisconsin–Madison. Ubiquitin ligases such as Deltex and Mib1 control receptor endocytosis; mechanistic interplay was resolved through collaborations involving Imperial College London and University of Toronto. Notch crosstalks with signaling modules like Wnt signaling pathway, Hedgehog signaling pathway, TGF-beta signaling pathway, and MAPK/ERK pathway to integrate morphogenetic cues—relationships explored in studies from Johns Hopkins University School of Medicine and University of Pennsylvania. Metabolic states and hypoxia responses mediated by factors such as HIF-1alpha also influence Notch transcriptional outputs, as shown in research at University of Oxford.

Involvement in Disease and Therapeutic Targets

Dysregulated Notch contributes to oncogenesis, exemplified by activating mutations in T-cell acute lymphoblastic leukemia and loss-of-function alterations in Alagille syndrome; clinical genetics efforts at Mayo Clinic and Boston Children's Hospital elucidated these links. Tumor angiogenesis and resistance mechanisms implicate DLL4–Notch signaling in oncology studies conducted at Dana-Farber Cancer Institute and pharmaceutical collaborations with Roche and Novartis. Gamma-secretase inhibitors and monoclonal antibodies targeting Notch receptors or ligands have been developed and trialed by industry partners including Pfizer and AstraZeneca, while concerns about gastrointestinal toxicity and on-target effects emerged in trials overseen by regulatory agencies like the Food and Drug Administration. Notch also features in cardiovascular defects, neurodegeneration research at National Institute on Aging, and congenital syndromes investigated by clinical centers such as Children's Hospital of Philadelphia.

Experimental Methods and Model Systems

Genetic screens in Drosophila melanogaster and targeted mutagenesis in Mus musculus have been foundational, with gene-editing technologies from Broad Institute and The Jackson Laboratory enabling conditional alleles and Cre-lox approaches. In vitro assays use co-culture systems, luciferase reporters, and chromatin immunoprecipitation performed in laboratories at Cold Spring Harbor Laboratory and EMBL. Live imaging of ligand–receptor dynamics employs fluorescent protein technologies developed at Howard Hughes Medical Institute and advanced microscopy platforms at Max Planck Institute for Biophysical Chemistry. High-throughput sequencing and transcriptomics from centers such as Wellcome Sanger Institute and GENOME consortia map Notch-dependent gene networks across tissues.

Category:Cell signaling pathways